BIRC5 and colorectal carcinoma: YM155, 1-(2-Methoxyethyl)-2-methyl-4, 9-dioxo-3-(pyrazin-2-ylmethyl)-4, 9-dihydro-1H-naphtho [2, 3-d] imidazolium bromide, is among the small-molecule survivin inhibitors investigated for its potential to treat CRC [23,24].